Concepedia

Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study

Jan W. Eriksson, Per Lundkvist, Per‐Anders Jansson, L. E. B. Johansson, Mats Kvarnström, Linda Moris, Tasso Miliotis, Gun‐Britt Forsberg, Ulf Risérus, Lars Lind,

Diabetologia · 2018 · 368 citations · 32 references

DOIFull text

Open access

Abstract

ClinicalTrials.gov NCT02279407 FUNDING: The study was funded by AstraZeneca.

References

32

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 11.6K citations · Full text

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey et al. · New England Journal of Medicine · 2017 · 7.5K citations · Full text

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

Stefano Romeo, Julia Kozlitina, Chao Xing et al. · Nature Genetics · 2008 · 3.3K citations · Full text

, , +13

The NAFLD fibrosis score

Paul Angulo, Jason M. Hui, Giulio Marchesini et al. · Hepatology · 2007 · 3.1K citations · Full text

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

Brent A. Neuschwander‐Tetri, Rohit Loomba, Arun J. Sanyal et al. · The Lancet · 2014 · 2.2K citations

, , +7